|
In vitro transcription (IVT) mRNA is widely used in basic research and application which provides a promising gene expression system for rapid and controllable induction of target proteins. Based on its safety and high efficiency, IVT mRNA is a powerful approach with potential applications in regenerative medicine, vaccination, cell engineering, and protein replacement therapy. IVT RNA synthesis with internal epigenetic modifications requires DNA template, enzymes, nucleotides, and buffer components. Not familiar with IVT mRNA technology or looking for a fast and effective service? Abnova provides fully service IVT mRNA encompassing DNA template production, mRNA production and mRNA QC to fulfill customer demand. Our technical support is available to accommodate additional requests and needs required by your experiments.
|
|
| |
| IVT mRNA Flowchart |
|
|
|
| |
| Advantages |
|
- Customized mRNA from several hundred to thousands of bases
- Optimized procedure of mRNA synthesis and purification
- Cell-free production without toxic chemicals
- Qualified RNA to match customer needs
- Ready for most downstream applications
- High-quality services with competitive prices
|
| |
| Specification |
|
| IVT Synthesis of mRNA Service Details |
| Services Items |
Lead Time |
| DNA Template Production |
Amplification of the gene of interest* and cloning it into the expression vector |
4 weeks |
|
Plasmid DNA preparation and purification |
| mRNA Production |
Linearized DNA preparation |
4 Days |
| In vitro transcription of linearized DNA into RNA |
| RNA capping |
| Capped RNA purification and quantification** |
| mRNA QC |
Integrity and purity: agarose gel electrophoresis of RNA |
2 Days |
| Protein expression: RNA transfection into cell and cell lysate subjected to Western blot analysis*** |
2 Weeks |
Note:
* Customers provide target sequence or DNA plasmid
** Adjustable amount of RNA yield to match customer demand
*** Optional task depends on customer needs
|
|
| |
| Capping Methods |
|
| Capping methods |
| Co-transcriptional Modification |
| Sequence |
RNA Sequence |
Capping sequence |
Cap Analog Features |
| Cap 0 |
GAUG |
3´-O-Me-m7G(5')ppp(5')GAUG |
Anti-Reverse
GTP competition |
| Cap 1 |
AUG |
m7G(5')ppp(5')(2'OMeA)pUG |
Without Anti-Reverse
Without GTP competition |
| Cap 1 |
AGG |
m7(3'OMeG)(5')ppp(5')(2'OMeG)pGG |
Anti-Reverse
Without GTP competition |
| Cap 1 |
GGG |
m7(3'OMeG)(5')ppp(5')(2'OMeA)pGG |
Anti-Reverse
GTP competition |
| Post-transcriptional Modification |
| Seqence |
RNA Sequence |
Capping sequence |
| Cap 0 |
AUG
UUG
GUG
CUG
|
m7G(5')ppp(5')AUG
m7G(5')ppp(5')UUG
m7G(5')ppp(5')GUG
m7G(5')ppp(5')CUG
|
| Cap 1 |
AUG
UUG
GUG
CUG
|
m7G(5')ppp(5')(2'OMeA)UG
m7G(5')ppp(5')(2'OMeU)UG
m7G(5')ppp(5')(2'OMeG)UG
m7G(5')ppp(5')(2'OMeC)UG
|
| Cap 1 |
AGG
GGG
UGG
CGG
|
m7G(5')ppp(5')(2'OMeA)GG
m7G(5')ppp(5')(2'OMeU)GG
m7G(5')ppp(5')(2'OMeG)GG
m7G(5')ppp(5')(2'OMeC)GG
|
| Cap 1 |
AGG
UGG
GGG
CGG
|
m7G(5')ppp(5')(2'OMeA)GG
m7G(5')ppp(5')(2'OMeU)GG
m7G(5')ppp(5')(2'OMeG)GG
m7G(5')ppp(5')(2'OMeC)GG
|
|
| |
| Nucleoside Modifications |
|
- Pseudouridine (Ψ)
- 5-methylcytidine (m5C)
- N1-methylpseudouridine (N1mΨ)
|
| |
| Cap0/Cap1 and Pseudouridine Modification Luciferase Signal |
|
|
|
| |
| |
|
For any inquiry, please contact : OEM@abnova.com
